WASh multicentre randomised controlled trial: water-assisted sigmoidoscopy in English NHS bowel scope screening by Rutter, Matthew et al.
  
 
P
R
IF
Y
S
G
O
L
 B
A
N
G
O
R
 /
 B
A
N
G
O
R
 U
N
IV
E
R
S
IT
Y
 
 
WASh multicentre randomised controlled trial: water-assisted
sigmoidoscopy in English NHS bowel scope screening
Rutter, Matthew ; Evans, Rachel; Hoare, Zoe; von Wagner, Christian; Deane,
Jill; Esmally, Shiran; Larkin, Tony; Edwards, Rhiannon Tudor; Yeo, Seow Tien;
Spencer, Llinos; Holmes, Emily; Saunders, Brian; Rees, Colin; Tsiamoulos,
Zacharias ; Beintaris, Iosif
GUT
DOI:
http://dx.doi.org/10.1136/gutjnl-2020-321918
E-pub ahead of print: 07/09/2020
Publisher's PDF, also known as Version of record
Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Rutter, M., Evans, R., Hoare, Z., von Wagner, C., Deane, J., Esmally, S., Larkin, T., Edwards, R.
T., Yeo, S. T., Spencer, L., Holmes, E., Saunders, B., Rees, C., Tsiamoulos, Z., & Beintaris, I.
(2020). WASh multicentre randomised controlled trial: water-assisted sigmoidoscopy in English
NHS bowel scope screening. GUT . https://doi.org/10.1136/gutjnl-2020-321918
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.
 09. Sep. 2020
  1Rutter MD, et al. Gut 2020;0:1–8. doi:10.1136/gutjnl-2020-321918
Endoscopy
ORIGINAL RESEARCH
WASh multicentre randomised controlled trial: water- 
assisted sigmoidoscopy in English NHS bowel 
scope screening
Matthew D Rutter   ,1,2 Rachel Evans,3 Zoe Hoare,3 Christian Von Wagner   ,4 
Jill Deane,1 Shiran Esmaily,1 Tony Larkin,5 Rhiannon Edwards,6 Seow Tien Yeo,6 
Llinos Haf Spencer,6 Emily Holmes,6 Brian P Saunders,7 Colin J Rees,2,8 
Zacharias P Tsiamoulos,7 Iosif Beintaris,1 On behalf of the WASh trial team
To cite: Rutter MD, Evans R, 
Hoare Z, et al. Gut Epub 
ahead of print: [please 
include Day Month Year]. 
doi:10.1136/
gutjnl-2020-321918
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
gutjnl- 2020- 321918).
1Gastroenterology, University 
Hospital of North Tees, 
Stockton- on- Tees, UK
2Population Health Sciences 
Institute, Newcastle University, 
Newcastle upon Tyne, UK
3North Wales Organisation for 
Randomised Trials in Health, 
Bangor University, Bangor, UK
4Behavioural Science and 
Health, University College 
London, London, UK
5Hartlepool, UK
6Centre for Health Economics & 
Medicines Evaluation, Bangor 
University, Bangor, UK
7Wolfson Unit for Endoscopy, St 
Mark’s Hospital, London, UK
8Gastroenterology, South 
Tyneside NHS Foundation Trust, 
South Shields, UK
Correspondence to
Professor Matthew D Rutter, 
Gastroenterology, University 
Hospital of North Tees, 
Stockton- on- Tees TS19 8PE, UK;  
 matt. rutter@ nhs. net
Received 20 May 2020
Revised 29 July 2020
Accepted 3 August 2020
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objectives The English Bowel Cancer Screening 
Programme invites 55 year olds for a sigmoidoscopy 
(Bowel Scope Screening (BSS)), aiming to resect 
premalignant polyps, thus reducing cancer incidence. A 
national patient survey indicated higher procedural pain 
than anticipated, potentially impacting on screening 
compliance and effectiveness. We aimed to assess 
whether water- assisted sigmoidoscopy (WAS), as 
opposed to standard CO2 technique, improved procedural 
pain and detection of adenomatous polyps.
Design The WASh (Water- Assisted Sigmoidoscopy) 
trial was a multicentre, single- blind, randomised control 
trial for people undergoing BSS. Participants were 
randomised to either receive WAS or CO2 from five sites 
across England. The primary outcome measure was 
patient- reported moderate/severe pain, as assessed by 
patients on a standard Likert scale post procedure prior 
to discharge. The key secondary outcome was adenoma 
detection rate (ADR). The costs of each technique were 
also measured.
Results 1123 participants (50% women, mean age 
55) were randomised (561 WAS, 562 CO2). We found 
no difference in patient- reported moderate/severe pain 
between WAS and CO2 (14% in WAS, 15% in CO2; 
p=0.47). ADR was 15% in the CO2 arm and 11% in 
the WAS arm (p=0.03); however, it remained above the 
minimum national performance standard in both arms. 
There was no statistical difference in mean number of 
adenomas nor overall polyp detection rate. There was 
negligible cost difference between the two techniques.
Conclusion In the context of enema- prepared 
unsedated screening sigmoidoscopies performed by 
screening- accredited endoscopists, no difference in 
patient- reported pain was seen when using either a CO2 
or WAS intubation technique.
Trial registration number ISRCTN81466870.
INTRODUCTION
Bowel cancer is the second most common cause of 
cancer death in the UK, and is estimated to cost the 
English National Health Service (NHS) £1.6 billion 
a year.1 Based on a large, UK randomised controlled 
trial (RCT),2 ‘Bowel Scope Screening’ (BSS), 
comprising a one- off sigmoidoscopy at 55 years, 
began roll- out in 2013, aiming to invite over 
650 000 people each year.
Sigmoidoscopy can be painful due to bowel 
distension and endoscope ‘looping’. Data from 
a BSS survey of 43 378 patients showed that 
39% of patients report moderate or severe pain.3 
Significance of this study
What is already known on this subject?
 ► Bowel cancer is the second most common 
cause of cancer death in the UK. Bowel 
Scope Screening (BSS) comprises a one- off 
sigmoidoscopy at 55 years. In a BSS survey, 
39% of patients reported moderate or severe 
pain. Studies indicate that water- assisted 
colonoscopy (using water rather than CO2 
insufflation) may decrease pain and increase 
adenoma detection rates (ADRs). However, no 
randomised controlled trial has assessed water- 
assisted sigmoidoscopy (WAS).
What are the new findings?
 ► Our trial did not show reduced patient pain 
using WAS for unsedated, enema- prepared 
screening sigmoidoscopy. Patients can be 
reassured that irrespective of insertion 
technique, pain in our study was much 
lower than previously reported. WAS cost on 
average 40 pence per person more than a CO2 
procedure.
How might it impact on clinical practice in the 
foreseeable future?
 ► There is no need for screening sigmoidoscopists 
to switch to a WAS technique, nor should 
national policy be amended. Caution should 
be given to monitoring ADR if WAS is used 
in enema- prepared sigmoidoscopies. Further 
research is required to explain why no 
difference was seen in pain, and why ADRs 
(although not overall polyp detection rates 
nor overall adenoma numbers) were lower, 
particularly as most trial endoscopists preferred 
the water- assisted technique.
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Maximising patient comfort is important as screening partici-
pation will reduce if public opinion is that it is unpleasant and 
anticipation of pain represents an important barrier to public 
participation.4 BSS success in reducing cancer incidence and 
mortality depends on optimising public participation: current 
uptake runs at only 43.7% (BSS data, March 2016), indicating 
that, with improved uptake, the impact on cancer reduction and 
mortality could double.
Water- assisted colonoscopy (WAC) involves water infusion 
during scope insertion, instead of traditional CO2 insuffla-
tion. Water infusion requires a lower volume (under 1 L) than 
CO2 (10 to 20 L), hence reducing distension and looping. Two 
different techniques have been described: water immersion 
(WI) and water exchange (WE).5 During WI, water is infused to 
inflate the lumen during scope insertion, then aspirated during 
withdrawal. In contrast, WE involves removal of the infused 
water and any bowel gas during insertion, to minimise luminal 
distension.5 Studies indicate that WAC decreases procedural 
pain.6–10 Some studies also show increased adenoma detection 
rates (ADRs).8 11 12 However, no RCT has assessed water- assisted 
sigmoidoscopy (WAS), nor has any water- assisted RCT been 
performed in the UK practice.
We aimed to investigate the effects of WAS in BSS. Our primary 
aim was to test the hypothesis that WAS would lead to decreased 
procedural pain, when compared with standard CO2- assisted 
insertion, resulting in better patient experience during BSS. Our 
key secondary aim was to study whether WAS affected the ADR. 
We also aimed to investigate the effects of WAS on ADR, other 
aspects of patients’ experience and technical aspects of sigmoid-
oscopy. Further, we aimed to assess the cost- effectiveness of the 
two techniques and to perform a discrete choice experiment to 
elicit patient preferences during sigmoidoscopy.
METHODS
Trial design
The WASh trial was a multicentre, prospective, two- armed, 
randomised, single- blinded trial designed to evaluate the effec-
tiveness of WAS in patients referred for BSS screening.13
Our primary outcome measure was patient- reported moderate/
severe pain, using the standard BSS Likert scale recorded after 
their procedure. Our key secondary outcome measure was ADR.
We developed the following trial success criteria—either:
 ► primary outcome achieved (WAS comfort score statistically 
superior) and no indication of ADR being inferior (defined 
as WAS ADR within 3% of control ADR); or
 ► primary outcome not achieved (but comfort score not statis-
tically inferior) but key secondary outcome achieved (ADR 
statistically superior)
Participants
Patients referred for screening sigmoidoscopy through the BSS 
programme were invited to take part in the study. Patients 
who had absolute contraindications to sigmoidoscopy, lacked 
capacity to give informed consent, had a previous distal colonic/
rectal resection or were receiving ongoing antithrombotic treat-
ment (excluding aspirin) were ineligible for recruitment into the 
study.13
Endoscopist training
All procedures were performed by screening- accredited endos-
copists trained in WAS. Training comprised a baseline question-
naire and a slide presentation (including videos). Endoscopists 
then attended a training day, including live demonstrations. 
Prior to trial commencement, endoscopists were required to 
have completed a training log of at least 20 WAS procedures to 
confirm competence.13
Procedures
Procedures were performed with enema preparation and without 
sedation, as mandated by BSS programme. The key principle 
of the WAS technique was to keep the lumen as collapsed as 
possible, thereby concertinaing the sigmoid colon, resulting in 
a straighter and shorter passage between the rectum and the 
descending colon, hence reducing the tendency for looping. The 
technique is described in detail in our published protocol.13 The 
technique comprised turning off the CO2 pump then infusing 
water as required to achieve adequate luminal views as the 
scope advanced. Suctioning of water/faecal residue and gas was 
performed as needed. While the technique was ideally performed 
without any gas insufflation, in common with other trials one 
or two short blasts of CO2 were permitted at the discretion of 
the endoscopist, but where possible, that insufflated gas was 
suctioned as soon as feasible, thus adhering to the principle of 
keeping the colon as collapsed as possible. CO2 insufflation was 
reinstated for extubation, which was identical in both arms, in 
accordance with standard BSS practice.13
Randomisation and blinding
Participants were allocated to WAS or CO2 on a 1:1 ratio using a 
dynamic adaptive algorithm created by the North Wales Organ-
isation for Randomised Trials in Health Clinical Trials Unit.14 
Participants were stratified by screening centre, scope diameter 
(adult or paediatric) and history of hysterectomy (men, women 
with a hysterectomy or women without a hysterectomy). Endos-
copists performing the procedure were not masked to treatment 
arm but where possible, patients were blinded to treatment. 
Primary data analysis was conducted by a blinded statistician.
Outcomes
The primary outcome was participant rated procedural pain on 
a 4- point Likert scale (dichotomised into a binary measure of 
none/mild versus moderate/severe). The key secondary outcome 
was ADR, which was calculated from the sigmoidoscopy proce-
dure alone. Other secondary outcomes included pain rated on a 
validated visual analogue scale (VAS) post procedure and prior 
to discharge, polyp detection, mean adenomas per procedure, 
overall procedure time, extent of insertion, use of Entonox, use 
of hand pressure, patient position changes, technique conversion 
rates, use of second enema, quality of mucosal views, looping 
and other procedure- related data. A patient experience question-
naire was completed 24 hours after the procedure. Participants 
remained in the trial for 14 days following their procedure, for 
adverse events identification purposes. We also aimed to define 
the sigmoidoscopist learning curve of the WAS technique during 
the training period. A full list of outcomes can be found in the 
study protocol paper.13
Statistics
A sample of 1100 patients was calculated to provide 80% power 
at a 5% significance level to detect a difference of 30% between 
the groups on the primary outcome of pain (none/mild versus 
moderate/severe); this included 5% attrition (PASS, V.15). We 
assumed an uptake rate of 20% and thus anticipated needing to 
invite 5500 people within 18 months.
The primary analysis was performed on an intention- to- treat 
basis. All statistical tests performed were two- sided using a 5% 
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significance level and 95% CI level. Results of secondary analysis 
were presented without adjustment for multiple comparisons. 
Outcomes with under 5% missing observations were conducted 
as complete case analysis, and if at least 5%, multiple imputation 
(MI) methods were adopted. The MI model included all factors 
that were used in the analysis models including allocation group, 
scope diameter, hysterectomy, history of IBS, trust and divertic-
ulosis. A fully defined statistical analysis plan was written, with 
review from the independent data- monitoring and trial steering 
committees, prior to completion of data collection.
Mixed effects regression models were run on scale outcomes 
and logistic regression models (binary, ordinal or multinomial) 
for categorical outcomes. Scope diameter, hysterectomy, history 
of IBS and diverticulosis were entered as fixed effect factors and 
screening centre as a random effect. All assumptions of fitted 
models were checked and evaluated to hold. The distribution 
of mean number of adenoma data was evaluated to be highly 
dispersed around zero; therefore, analysis using a zero- inflated 
negative binomial model was conducted.
Economic evaluation
We evaluated the cost- effectiveness of WAS versus CO2 sigmoid-
oscopy. We measured costs from an NHS perspective, focus-
sing on the direct medical costs of both procedures. Only if we 
observed a significant difference in effectiveness in terms of the 
primary outcome measure (pain) were we to progress to a full 
cost- effectiveness analysis.15
RESULTS
Recruitment
Overall, 2845 patients were screened for inclusion in the 
trial, of whom 1130 were recruited (40%; figure 1) between 
December 2017 and June 2019. Of the 1130 recruited, two 
participants were removed from the study before randomisation 
and following randomisation, a further five participants were 
removed due to protocol deviations. The final analysis data set 
therefore comprised 1123 participants (561 WAS; 562 CO2). 
Two patients withdrew from the study following randomisation, 
Figure 1 Participant CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials; WAS, water- assisted sigmoidoscopy
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however, did not withdraw consent to use their data. No patient 
was lost to follow- up.
Missing data
Most of the same- day outcome measures had minimal missing 
data (below 2%) and complete case analysis was conducted on 
these. The next- day patient experience questionnaire outcomes 
had more missing data (24% to 25%); therefore, MI techniques 
were adopted.
Demographics
Patient characteristics are detailed in table 1. Participants were 
50% men, 43% women without hysterectomy and 7% women 
with previous hysterectomy. The mean age was 55 years. History 
of IBS was present in 10% participants. Diverticulosis was not 
present in 79% of participants, DICA (Diverticular Inflamma-
tion and Complication Assessment) grade 1 was present in 17% 
and DICA grade 2 diverticulosis in 3%.16
Procedural pain
When asked immediately following the procedure to reflect 
on procedural pain, 44% of participants reported no pain, 
40% mild, 14% moderate and 2% severe pain. The mean VAS 
pain score reported immediately after the procedure was 21.1 
(SD 22.5; median 10, IQR 3 to 30). Of the 857 (76%) who 
responded to the next- day survey, 28% recalled no procedural 
pain, 46% mild pain, 23% moderate and 3% severe pain. Of 854 
respondents, 57% felt that the procedure was less painful than 
expected, 12% felt it was more painful and 31% stated it was as 
expected. Those who felt the procedure was more painful than 
expected (12%) were significantly lower than in the national 
survey (25%) (p<0.01, χ2 test).3
The results of the logistic (binary) regression analysis (table 2) 
conducted on the primary outcome of patient- reported moderate 
or severe pain (judged immediately after the procedure) revealed 
no statistically significant difference between the WAS and CO2 
arms (OR=1.13, 95% CI 0.81 to 1.59, p=0.47), with predictive 
marginal estimates of 14% in WAS and 15% in CO2 (table 3). 
Other patient pain data is included in online supplementary 
table 1.
Polyp detection
Of 1123 participants, 290 (26%) had at least one polyp and 113 
(10%) had at least one adenoma (online supplementary table 
2). Most patients with adenomas (88%) had only one; the most 
detected being five adenomas in one patient. Logistic regression 
analysis, detailed in table 2, revealed that the key secondary 
outcome of ADR was statistically significantly higher in the CO2 
group (OR=1.45, 95% CI 1.03 to 2.04, p=0.03). The predic-
tive marginal estimates indicate ADR to be 11% in the WAS 
group, as opposed to 15% in the CO2 group (table 3). The mean 
number of adenomas were 10 per 100 procedures in WAS and 
15 per 100 procedures in CO2 (NS; not significant). Polyp detec-
tion was 143 (25 per 100) in WAS and 147 (26 per 100) in CO2 
group (NS). Median and IQR for WAS and CO2 groups were 
identical for all polyp sizes (median 3 mm, IQR 2 to 4 mm) and 
maximal polyp size per patient (median 3 mm, IQR 2 to 5 mm).
Other procedural outcome measures
Sixty- one per cent of procedures reached at least the descending 
colon (online supplementary table 2). Retroflexion was 
performed in 94%. Most procedures did not use Entonox 
(90%), need a re- enema (94%), external hand pressures (98%) 
or patient position changes (78%). The most common endo-
scope model used was the Olympus 260 series (76%). The mean 
length of scope inserted was 46 cm (SD 14.59).
Eighty per cent of procedures had good or excellent mucosal 
views on the Boston Bowel Preparation Scale (BBPS).17 Mucosal 
views were statistically inferior in the CO2 group (OR=0.77, 
95% CI 0.61 to 0.97, p=0.02). Excellent prep was more 
common in the WAS group, whereas inadequate prep rates were 
the same in both groups.
The mean overall procedure time was 7.68 (SD 4.30) minutes. 
After adjustment, those in the WAS group have a longer insertion 
(4.62 min) and overall procedure time (8.83 min) compared with 
the CO2 group (4.08 min and 8.12 min, respectively; p<0.01 for 
both).
Overall, 5% of procedures required a technique conversion: 
significantly more from WAS to CO2 (7%) than from CO2 to 
WAS (2%); (OR=0.26, 95% CI 0.13 to 0.52, p<0.01).
All 50 adverse events (in 47 patients) were classed as ‘expected’ 
and not serious, comprising 21 patients (45%) in the WAS group 
and 26 patients (55%) in the CO2 group (χ
21 =0.55, p=0.46).
No other outcomes revealed statistically significant differences 
between WAS and CO2 groups. Raw data of pain, procedure- 
related data and patient experience are presented in the online 
supplementary tables and analysis results detailed in table 2.
Table 1 Demographics and baseline characteristics
Overall N (%) 
(n=1123)
WAS N (%)
(n=561)
CO2 N (%)
(n=562)
Participant age* 55 (0.41) 55 (0.36) 55 (0.45)
Gender
  Men 562 (50) 279 (50) 283 (50)
  Women 561 (50) 282 (50) 279 (50)
Hysterectomy
  Women with hysterectomy 81 (7) 43 (8) 38 (7)
  Women without hysterectomy 480 (43) 239 (43) 241 (43)
History of IBS
  No 1006 (90) 502 (90) 504 (90)
  Yes 117 (10) 59 (10) 58 (10)
Diverticulosis
  No 888 (79) 458 (82) 430 (77)
  Grade 1 (<15, no rigidity or no 
stenosis)
194 (17) 89 (16) 105 (19)
  Grade 2 (>15 or rigidity or 
stenosis)
38 (3) 13 (2) 25 (4)
  Missing 3 (<1) 1 (<1) 2 (<1)
Scope diameter
  Adult 986 (88) 492 (88) 494 (88)
  Paediatric 137 (12) 69 (12) 68 (12)
Trust
  North Tees and Hartlepool 
Hospitals NHS Trust
673 (60) 336 (60) 337 (60)
  Northumbria Healthcare NHS 
Foundation Trust
177 (16) 88 (16) 89 (16)
  County Durham and Darlington 
Foundation Trust
132 (12) 68 (12) 64 (11)
  London North West Healthcare 
NHS Trust
80 (7) 39 (7) 41 (7)
  South Tyneside Foundation 
Trust
61 (5) 30 (5) 31 (6)
*Mean (SD) reported.
NHS, National Health Service; WAS, water assisted sigmoidoscopy.
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Other patient questionnaire outcome measures
Of the 856 patients who responded to the question on embar-
rassment experienced during the procedure, 53% reported 
none, 39% reported mild, 8% moderate and less than 1% 
severe embarrassment (online supplementary table 3). Of the 
858 patients who rated their experience, 69% were very satis-
fied, 26% satisfied, 3% neither satisfied or dissatisfied, and 2% 
dissatisfied. When asked if they would have the same procedure 
Table 2 Results of analysis conducted on study outcomes
Outcome OR (SE)
95% CI
P valueLower Upper
Logistic regression
  Pain (none/mild versus moderate/severe) (PO) 1.13 (0.20) 0.81 1.59 0.47
  ADR (no, yes) (KSO) 1.45 (0.25) 1.03 2.04 0.03
  Pain (none/mild/moderate versus severe) 1.77 (0.87) 0.68 4.62 0.24
  Maximum extent of insertion (descending or greater, no further than sigmoid) 1.12 (0.15) 0.87 1.45 0.39
  Entonox use (no or yes) 1.32 (0.28) 0.87 2.00 0.19
  Need for re- enema (no or yes) 1.32 (0.34) 0.79 2.20 0.28
  Need for patient position changes (no or yes) 1.15 (0.18) 0.84 1.55 0.38
  Technique conversion (no or yes) −0.26 (0.09) 0.13 0.52 <0.01
Ordinal logistic regression
  Pain felt 24 hours (none, mild, moderate or severe) 1.21 (0.17) 0.93 1.59 0.15
  Pain expected (less painful, as expected or more) 1.23 (0.17) 0.94 1.61 0.13
  Embarrassment (none, mild, moderate or severe) 1.02 (0.13) 0.79 1.32 0.86
  Satisfaction (very dissatisfied, neither, satisfied or very satisfied 0.87 (0.12) 0.66 1.15 0.33
  Repeat procedure (No, not sure or yes) 0.66 (0.26) 0.30 1.44 0.29
  Recommend procedure (No, not sure or yes) 1.19 (0.42) 0.59 2.38 0.63
  Abdominal pain (none, mild, moderate or severe) 1.33 (0.20) 0.99 1.80 0.06
  Nausea (none, mild, moderate or severe) 1.95 (0.78) 0.89 4.27 0.10
  Faint feeling (none, mild, moderate or severe) 0.97 (0.28) 0.55 1.71 0.91
  Bloating (none, mild, moderate or severe) 1.22 (0.17) 0.92 1.61 0.17
  Bottom soreness (none, mild, moderate or severe) 1.07 (0.22) 0.72 1.59 0.75
  Soiling (none, mild, moderate or severe) 1.28 (0.36) 0.74 2.23 0.38
  Bleeding (none, mild, moderate or severe) 1.50 (0.60) 0.69 3.28 0.31
  Sleep disturbance (none, mild, moderate or severe) 0.95 (0.25) 0.57 1.58 0.84
  Quality of mucosal views (BBPS) (inadequate, poor, good or excellent) −0.77 (0.09) 0.61 0.97 0.02
Mixed regression models COEF (SE)
  Patient procedural pain (VAS) 1.59 (1.28) −0.92 4.11 0.22
  Sigmoid insertion time −0.54 (0.15) −0.84 −0.24 <0.01
  Sigmoid withdrawal time −0.16 (0.17) −0.50 0.18 0.35
  Overall procedure time −0.70 (0.24) −1.17 −0.23 <0.01
  Length of scope inserted −0.04 (0.79) −1.58 1.50 0.96
Zero- inflated Poisson model
  Mean adenomas per procedure 0.10 (0.18) −0.26 0.45 0.60
ADR, adenoma detection rate; BBPS, Boston Bowel Preparation Scale; COEF, coefficient; KSO, key secondary outcome; PO, primary outcome; VAS, visual analogue scale; WAS, water- assisted 
sigmoidoscopy.
Table 3 Predictive marginal estimates of PO, KSO and other statistically significant secondary outcomes
Outcome
WAS
marginal estimate (SE)
95% CI
CO2
marginal estimate (SE)
95% CI
Lower Upper Lower Upper
Logistic regression
  PO: pain 0.14 (0.03) 0.08 0.20 0.15 (0.03) 0.09 0.22
  KSO: ADR 0.11 (0.02) 0.08 0.15 0.15 (0.02) 0.11 0.20
Ordinal logistic regression
  Quality of mucosal views (BBPS)
   Inadequate 0.02 (0.004) 0.01 0.02 0.02 (0.006) 0.01 0.03
   Poor 0.16 (0.03) 0.11 0.21 0.19 (0.03) 0.13 0.25
   Good 0.54 (0.02) 0.51 0.58 0.55 (0.02) 0.52 0.59
   Excellent 0.28 (0.04) 0.21 0.36 0.24 (0.04) 0.17 0.30
Mixed regression
  Sigmoid insertion time 4.62 (0.47) 3.69 5.55 4.08 (0.47) 3.16 5.01
  Overall procedure time 8.83 (1.09) 6.69 10.97 8.12 (1.09) 5.98 10.27
ADR, adenoma detection rate; BBPS, Boston Bowel Preparation Scale; COEF, coefficient; KSO, key secondary outcome; PO, primary outcome; WAS, water- assisted sigmoidoscopy.
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again, 97% said yes, less than 1% said no and just under 3% 
were unsure. When asked whether they would recommend the 
procedure to a friend, 97% said yes, under 3% said they were 
unsure and less than 1% said no (online supplementary table 3).
Of those responding to the questionnaire, 66% reported no 
abdominal pain or cramps, 28% reported mild, 5% moderate 
and 1% reported severe abdominal pain or cramps. No bleeding 
was reported by 97%, mild by 3%, moderate by less than 1% 
but none reported severe bleeding. No sleep disturbance was 
reported by 93%, mild by 5%, moderate by 2% and severe by 
less than 1%. No bloating/wind was reported by 49%, mild by 
42%, moderate by 8% and severe by 1%. No bottom soreness 
was reported by 86%, mild by 13%, moderate by 1% and severe 
by less than 1%. No soiling was reported by 94%, mild by 5%, 
moderate by 1% and none reported severe soiling. No nausea/
vomiting was reported by 97%, mild by 3%, moderate by less 
than 1% and severe by less than 1%. No faintness/dizziness was 
reported by 94%, mild by 6%, moderate by less than 1% and 
severe by less than 1% (online supplementary table 3).
Subgroup analyses
Subgroup analyses were conducted on history of IBS, diver-
ticulosis, scope diameter, scope model, extent of procedure, 
hysterectomy/sex, endoscopist WAS competence prior to study 
training, study period (first half, second half), BBPS and polyp 
detection. None aided interpretation of the results with regards 
to the primary outcome of patient- reported pain. Regarding the 
key secondary outcome of ADR, the only result of interest was 
that endoscopists without prior WAS experience had a signifi-
cantly lower ADR in the WAS arm compared with the CO2 arm 
(no prior experience predictive marginal means ADR 10% in 
WAS and 15% in CO2, p=0.01; prior experience ADR was 21% 
in WAS and 21% in CO2). For prior experience subgroup, the 
mean number of adenomas were 19 per 100 procedures in both 
WAS and CO2 and for those with no prior experience, the mean 
adenomas were 8 per 100 procedures in WAS and 14 per 100 
procedures in CO2. It should be noted that the prevalence of 
procedures conducted by an experienced endoscopist was low 
and data for it was not collected a priori for analysis; hence, 
these results should be interpreted with caution.
Endoscopist survey
After trial recruitment had finished, the 15 participating endos-
copists were asked to complete a questionnaire. Self- reported 
lifetime experience ranged from 38 to 400 independent water- 
assisted procedures (median 100), with a success rate ranging 
from between 60% and 70% to 95% (median 90%). Positive 
attitude was expressed by 14/15 (93%) towards the water- 
assisted technique, one was neutral. Ten (67%) preferred the 
water- assisted technique, one preferred CO2 insertion and four 
were neutral. All stated that they were likely to use the water- 
assisted technique in their ongoing endoscopy practice.
Costs of the two procedures
As there was no difference in the primary outcome measure of 
pain experienced by patients, we assessed the costs of the two 
procedures rather than performing a full cost- effectivesness anal-
ysis. With Reference to NHS costs of £388 for diagnostic flex-
ible sigmoidoscopy with biopsy on an outpatient basis, 19 years 
and over,18 we estimated WAS to be £0.40 more per procedure 
per patient. The CO2 cost £0.03 per litre, whereas water was of 
slightly higher cost; hence, the difference in price between both 
procedures.
DISCUSSION
This is one of the largest RCTs assessing a water- assisted endo-
scopic technique to be performed to date, and the first in the 
UK. We believe it is also the first trial to assess the technique in 
enema- prepared sigmoidoscopy.
Pain
We found no difference in pain between CO2 and WAS—thus, 
our study proved negative according to its primary outcome 
measure. This might be because the technique offers no advan-
tage in patient pain, at least in the context of enema- prepared, 
unsedated sigmoidoscopies performed by screening- accredited 
endoscopists. Although this is contrary to other trials, our results 
are plausible as studies to date have all been for colonoscopy 
rather than sigmoidoscopy. Moreover, the BSS has an endosco-
pist accreditation process, which may mean the standard tech-
nique is higher quality than in most other services. CO2 is also 
mandated in the BSS, whereas in many studies, air was used 
rather than CO2 insufflation: CO2 causes less pain than air.
19 Of 
note, the overall rates of moderate and severe pain in our trial 
were significantly lower than in the national survey conducted 
prior to the trial (p<0.01, χ2 test),3 perhaps indicating that 
screening endoscopists have improved their sigmoidoscopy 
technique since BSS roll- out, or possibly due to the Hawthorne 
effect (trial sigmoidoscopists’ performance improving due to 
their knowledge of being observed).
Several other potential explanations were explored. First, it 
is possible that trial endoscopists were inadequately trained in 
the water- assisted technique; however, subgroup analysis failed 
to show any difference in outcome between the first and second 
half of the study, nor was the outcome different on subgroup 
analysis of endoscopists with prior experience of the technique. 
Moreover, after the trial, the majority of endoscopists expressed 
a preference for water- assisted intubation, implying that they felt 
they had mastered the technique. While the underlying principle 
of the water- assisted technique that we taught was to collapse 
the colon down as much as possible to create a concertinaed 
sigmoid and straighter path from the rectum to the descending 
colon, we did not mandate a full water- exchange technique—it is 
possible that either the full water- exchange technique or a ‘cork-
screw hook’ rather than push technique is required to improve 
comfort.
Second, the technique might have been hampered by inade-
quate cleansing from enema- preparation; however, no differ-
ence in outcome was identified on subgroup analysis limited to 
cases with good or excellent prep.
Third, most endoscopes did not have a dedicated irri-
gator channel, potentially hampering the technique; however, 
subgroup analysis limited to endoscopes with an irrigator 
channel failed to show a difference.
Fourth, the post- procedure assessment of pain used in our 
study might have been too insensitive to detect true differences; 
however, this validated score did reveal a difference between the 
overall trial pain levels compared with the prior national survey.3 
Also, no difference was seen using the more sensitive visual 
analogue score; thus, one can argue that any undetected differ-
ence would likely be too subtle to be of clinical significance.
Fifth, unlike in colonoscopy, where the endoscopist must reach 
a fixed landmark (the caecum), in the BSS, the endoscopist is 
tasked with intubating as far as is possible within the limitations 
of the bowel prep and patient comfort—thus, an endoscopist 
might opt to cease intubation early on if a patient experiences 
pain, potentially removing a cohort of patients who would have 
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experienced substantial pain with ongoing intubation. We believe 
this is a likely explanatory factor for the lower levels of pain 
experienced overall in our trial compared with the earlier BSS 
survey, where depth of intubation was more than in our trial—it 
is also possible that there has been a genuine improvement in 
technique, hence sigmoidoscopy comfort in recent years. Never-
theless, our trial revealed no difference in depth of intubation 
between the two arms.
Planned subgroup analyses of specific patient cohorts (men/
women without hysterectomy/women with hysterectomy, IBS/
no IBS, and no diverticulosis/DICA1/DICA2) failed to show 
any difference in pain between the CO2 and water- assisted 
techniques.
Polyp detection
In our key secondary outcome measure, ADR was above the 
minimum BSS performance standard in both arms but was 
significantly higher in the CO2 arm compared with WAS. 
This could not be explained by any difference in bowel prep 
quality, nor extubation times. This finding was unexpected, 
as several prior trials reported higher ADR with a water- 
exchange intubation technique, although it should be noted 
that our trial was water- assisted rather than full water- 
exchange technique. As there was no significant differ-
ence between trial arms in the total number of adenomas 
detected or the polyp detection rate, it is possible that the 
ADR difference was a chance occurrence. However, it is 
feasible that the difference was genuine, either due to the 
technique per se (eg, from reduced detection due to subop-
timal views on intubation), a learning curve for the tech-
nique (unfamiliarity with the underwater view or distraction 
by performing the new technique), or the trial protocol (the 
trial protocol specified that polyps should be removed on 
extubation where possible). Although one of our subgroup 
analyses revealed no difference between the first and second 
half of the trial, another subgroup analysis revealed that the 
lower ADR was limited to endoscopists without prior expe-
rience in the water technique, implying that there may be 
a longer learning curve for the WAS technique that we had 
appreciated.
Cost of WAS and CO2 techniques
There was negligible difference in cost between the two 
procedures.
Limitations
As with most endoscopy trials, it was not possible to blind the 
endoscopist to intervention arms, hence there might have been 
deliberate or inadvertent bias for either CO2 or WAS intubation 
technique. Most patients included in our trial were also recruited 
at one site (North Tees).
CONCLUSION
In conclusion, our trial did not show reduced patient pain 
using a water- assisted (cf. standard CO2- assisted) technique 
during unsedated, enema- prepared screening sigmoidos-
copy performed by screening- accredited endoscopists. 
Patients can be reassured that irrespective of insertion 
technique, pain in our study was much lower than previ-
ously reported. There is no need for screening sigmoid-
oscopists to switch to a WAS technique, nor should the 
BSS programme amend national policy. Caution should be 
given to monitoring ADR if WAS is used in enema- prepared 
sigmoidoscopies. Further research is required to explain 
why no difference was seen in pain, and why ADRs 
(although not overall polyp detection rates nor overall 
adenoma numbers) were lower, particularly as most trial 
endoscopists preferred the water- assisted technique and 
previous colonoscopy trials have suggested water- assisted 
techniques were superior.
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